Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MabpharmHKSE:02181 +1.23%40 Days Payable is 136.49 as of Dec. 2025, which is 27% below its 10-year median of 187.49. GuruFocus rates HKSE:02181 with a GF Score™ of 40/100 and a GF Value™ of HK$1.97 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 702 Biotechnology companies, Mabpharm ranks better than 51.71% on this metric.
Mabpharm's average Accounts Payable for the
six
months ended in Dec. 2025 was HK$32.6 Mil. Mabpharm's Cost of Goods Sold for the
six
months ended in Dec. 2025 was HK$43.6 Mil.
Hence, Mabpharm's Days Payable for the
six
months ended in Dec. 2025 was 136.49.
The historical rank and industry rank for Mabpharm's Days Payable or its related term are showing as below:
HKSE:02181'
s Days Payable Range Over the Past 10 Years
Min: 103.23 Med: 187.49 Max: 412.45
Current: 118.82
During the past 9 years, Mabpharm's highest Days Payable was 412.45. The lowest was 103.23. And the median was 187.49.
HKSE:02181's Days Payable is ranked better than 51.71% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs HKSE:02181: 118.82
Mabpharm's Days Payable
increased
from Dec. 2024 (88.85) to Dec. 2025 (136.49).
It may suggest that Mabpharmdelayed paying its suppliers.
Mabpharm Days Payable Related Terms
Mabpharm Days Payable Historical Data
* Premium members only.
The historical data trend for Mabpharm's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02181 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Mabpharm's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabpharm Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabpharm's Days Payable distribution charts can be found below:
* The bar in red indicates where Mabpharm's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mabpharm's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabpharm (HKSE:02181) has a Days Payable of 136.49 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mabpharm and its competitors. This is 27% below median its historical median of 187.49. Over the past decade, Mabpharm's Days Payable has ranged from 103.23 to 412.45. According to the industry distribution chart, Mabpharm ranks #339 out of 702 companies in the Biotechnology industry, placing it in the top 48.3%.
Is Mabpharm's Days Payable too high?
Mabpharm's current Days Payable of 136.49 is 27% below median its 10-year median of 187.49. Over the past 10 years, this metric has ranged from a low of 103.23 to a high of 412.45. The Biotechnology industry median Days Payable is 113.10. Mabpharm's value of 136.49 is 20.7% above this industry median. Based on the distribution chart, Mabpharm ranks #339 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mabpharm has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mabpharm's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabpharm ranks #339 out of 702 companies for Days Payable. This puts Mabpharm in the upper half of its industry. The industry median Days Payable is 113.10. Mabpharm's value of 136.49 is 20.7% above this benchmark. Historically, Mabpharm's own Days Payable has ranged from 103.23 to 412.45 over the past decade. While the company's 10-year median is 187.49 vs. the industry median of 113.10, Mabpharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mabpharm's current Days Payable of 136.49 is 20.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mabpharm and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mabpharm's current Days Payable is 136.49, which is 27% below median its own 10-year median of 187.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabpharm stock overvalued right now?
Based on GuruFocus' analysis, Mabpharm (HKSE:02181) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.97, compared to a current price of HK$0.41 — trading 79.2% below its estimated fair value. The current Days Payable is 136.49, which is 27% below median its 10-year median of 187.49 and 20.7% above the Biotechnology industry median of 113.10. Mabpharm's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mabpharm (HKSE:02181), the current Days Payable is 136.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mabpharm (HKSE:02181) Overvalued in 2026?
Based on GuruFocus' analysis, Mabpharm stock appears to be undervalued.
The current stock price of HK$0.41 is trading 79.2% below its estimated GF Value™ of HK$1.97.
GuruFocus considers Mabpharm to be Possible Value Trap.
Key valuation signals for HKSE:02181:
Days Payable: 136.49 (27% below median its 10-year median of 187.49)
GF Value™: HK$1.97 vs. price of HK$0.41 (79.2% below fair value)
Industry Position: 20.7% above the Biotechnology median (#339 of 702)
No single metric tells the full story. See the HKSE:02181 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
40GF Score
Get the complete analysis for HKSE:02181
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02181 has been successfully added to your 
